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Abstract
Background: Gut microbiota play a major role in digestion and energy conversion of nutrients. Antibiotics, such as
avoparcin (a vancomycin analogue), and probiotics, such as Lactobacillus species, have been used to increase weight in farm
animals. We tested the effect of antibiotics given for infective endocarditis (IE) on weight gain (WG).
Methodology/Principal Findings: Forty-eight adults with a definite diagnosis of bacterial IE (antibiotic group) were
compared with forty-eight age-matched controls without IE. Their body mass index (BMI) was collected at one month
before the first symptoms and one year after hospital discharge. The BMI increased significantly and strongly in vancomycin-
plus-gentamycin–treated patients (mean [6SE] kg/m
2, +2.3 [0.9], p=0.03), but not in controls or in patients treated with
other antibiotics. Seventeen patients had a BMI increase of $10%, and five of the antibiotic group developed obesity. The
treatment by vancomycin-plus-gentamycin was an independent predictor of BMI increase of $10% (adjusted OR, 6.7; 95%
CI, 1.37–33.0; p=0.02), but not treatment with other antibiotics. Weight gain was particularly high in male patients older
than 65 who did not undergo cardiac surgery. Indeed, all three vancomycin-treated patients with these characteristics
developed obesity.
Conclusions/Significance: A major and significant weight gain can occur after a six-week intravenous treatment by
vancomycin plus gentamycin for IE with a risk of obesity, especially in males older than 65 who have not undergone surgery.
We speculate on the role of the gut colonization by Lactobacillus sp, a microorganism intrinsically resistant to vancomycin,
used as a growth promoter in animals, and found at a high concentration in the feces of obese patients. Thus, nutritional
programs and weight follow-up should be utilized in patients under such treatment.
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Introduction
The prevalence of obesity is a major world health problem that
is rapidly increasing in developing countries [1,2]. Currently, more
than half of the US population is overweight [3,4] and thus
exposed to a high cardiovascular risk. Obesity results from a
mixture of genetic background and environmental factors,
including food availability, social networks [5], high fat diet, and
physical inactivity [6,7]. Recent evidence suggests that gut
microbiota play a major role in the digestion an energy conversion
of nutrients [8,9].
Moreover, metagenomics studies have demonstrated that the
gut microbiota composition may be altered by environmental
modifications [10] and differs in lean vs. obese animals and
humans [11,12], suggesting its potential role in the pathogenesis of
obesity [13,14]. A recent 16S rRNA sequencing-based investiga-
tion showed that Firmicutes are increased in obese mammals [15].
Additionally, a large body of experimental evidence and empirical
data from the food industry has shown that Firmicute probiotics (e.g.,
Lactobacillus and Enterococcus) and antibiotics that modify the gut
microbiota can act as growth promoters, increasing the size and
weight of animals [16,17,18]. Moreover, we recently found that
Lactobacillus was significantly increased in the stools of obese
patients [19]. Avoparcin, an analogue of vancomycin, has been
largely used in farm animals [20] and is active on most Firmicutes,
with the notable exception of Lactobacillus species.
Similar growth effects have been observed in children with the
long-term use of tetracycline [21], and a possible link between
increased antibiotic use and obesity has been proposed [22]. The
mechanisms by which antibiotics improve growth performance are
not well known, and the selection of gut microorganisms with
potential growth promoting effects is one of hypotheses [14,23].
Lactobacillus species are thought to be growth promoters, with an
intrinsic vancomycin-resistance [24,25] and a probiotic activity
[26,27]. Their presence has been shown to dramatically increase
food conversion and weight increase in chickens [28], and some
reports suggest similar effects in children [29].
Taking advantage of a large cohort of patients treated for
infective endocarditis (IE) in our center over many years, we
sought to determine the impact of antibiotic therapy, given during
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9074a long period at high doses levels, on body weight changes. We
retrospectively compared the body mass index (BMI) changes of
patients one month before the occurrence of the first symptoms
compatible with IE and one year after hospital discharge for a
group of patients treated for definite IE and a control group.
Methods
Ethics Statement
Written informed consent was obtained from all participating
patients and approved by the institutional review board (Comite ´
d’Ethique de l’IFR 48) under reference 08–002.
Patients
We conducted a retrospective analysis in consecutive adults
referred for a suspicion of IE to the Department of Cardiology of
La Timone Hospital, Marseille, France, from January 2002 to
December 2007. A structured, standardized questionnaire was
used to collect demographic, clinical, biological, microbiological,
echocardiographic, and therapeutic data in all of these patients.
The modified Duke criteria [30] were applied to all suspected
cases, which were characterized as definite, probable, or excluded.
The weight, height, and BMI (weight [Kg]/height
2 [m
2]) of each
patient were collected at two different times, one month before the
first symptoms (baseline) and one year after discharge, during
systematic and standardized consultations or phone contacts.
Finally, we included two groups of patients. The ‘‘Antibiotic
group’’ was formed by patients who were definitely diagnosed with
bacterial IE and treated by intravenous antibiotics for at least four
weeks. We defined the control group (same sample size) as
consecutives patients first suspected to have IE but finally receiving
an excluded diagnosis. Controls did not receive antibiotics for
more than fifteen days. The exclusion criteria were: the absence of
weight or height data at baseline or at one year, all conditions (IE
or others) responsible for a major limitation of physical activity,
and changes of weight related to edema or ascites.
Antibiotic Therapy
The patients in the Antibiotic group received antibiotic therapy
according to a standardized local protocol [31]. The patients were
stratified according to the type of antibiotics used in association
with gentamycin, namely vancomycin, amoxicillin, or other
antibiotics (including patients treated with oxacillin and those
who alternatively received amoxicillin and vancomycin). The
duration of antibiotic therapy ranged from four to six weeks. For
each case of IE, the decision of valvular surgery was taken in a
multidisciplinary way. In controls with a non-infective valvular
heart disease, the indications of cardiac surgery were based on
international recommendations [32].
Questionnaire of Lifestyle
A standardized questionnaire about their life habits was
retrospectively proposed within one year after hospital discharge
to all of the patients in the two groups. This questionnaire included
the following questions: did you quit smoke? (yes/no); were you on
a hypocaloric diet because of a weight gain? (yes/no); did you
consume probiotics? (yes/no); and did you increase or decrease
your physical activity? (increase, decrease, or no change).
Statistical Analysis
The baseline BMI was that obtained one month before the first
symptoms. The changes of BMI at one year were compared
between the two groups, and we tested the potential role of the
different antibiotics used. Proportions were compared using the
Chi-squared test or the Fisher’s exact test. For the continuous
variables, the Wilcoxon test and Mann-Whitney test were used for
comparison between the two groups. Logistic regression was used
to determine the predictors of an increase of BMI $10% at one
year. The following variables were tested as potential predictors:
age, sex, cancer, chronic renal insufficiency, the Charlson
comorbidity index [33], stroke, heart failure, cardiac surgery
within the year after admission, and the type of antibiotic used in
association with gentamycin (i.e., vancomycin, amoxicillin, or
other antibiotics). P,0.05 was considered significant, and a
Bonferroni’s correction was used in case of multiple comparisons.
All statistical analyses were performed using EpiInfo software
version 3.4.1 (Centers for Disease Control and Prevention,
Atlanta, GA, USA).
Results
Patient Characteristics
During the period of study, 2,533 patients were referred for a
suspicion of IE. Among them, 48 patients with definite IE fulfilled
the inclusion criteria, had no exclusion criterion, and were thus
included in the ‘‘Antibiotic group’’. The control group was then
formed by another 48 consecutive patients that received an
excluded diagnosis of IE and did not meet the study’s exclusion
criterion.
The clinical characteristics of the two groups are summarized in
the Tables 1 and 2. The weight and BMI one month before the
first symptoms (baseline) did not differ significantly between the
two groups (Antibiotic vs. Control group; weight [Kg], 75.2617
vs. 69 .8615, p=0.10; BMI [Kg/m
2], 25.365 vs. 23.964,
p=0.14). No significant difference was observed between the two
groups in terms of age, sex, diabetes, chronic renal insufficiency,
comorbidity index, previous heart disease, presence of prosthetic
valve, history of heart failure, or smoking behavior. However, a
history of cancer was more frequently noticed in the Antibiotic
group (20.8% vs. 4.2%, p=0.03), and a cardiac surgery within one
year after admission was also performed more frequently in the
Antibiotic group (72.9% vs. 16.7%, p,0.0001).
In the Antibiotic group, 28 patients received amoxicillin for four
to six weeks in association with gentamycin for six, four, three, or
two weeks in five, three, three, or 17 patients, respectively. Eleven
patients received vancomycin for four to six weeks in association
with gentamycin for six, two, or one weeks in six, three, or eight
patients, respectively. Nine patients received other antibiotics.
BMI Changes
The BMI increased significantly in the Antibiotic group (mean
[6SE] Kg/m
2, +1.1 [0.5], p=0.02) but not in the controls (mean
[6SE] Kg/m
2, 20.2 [0.2], p=0.38). After stratification according
to the type of antibiotics, BMI significantly and strongly increased
only after treatment by vancomycin+gentamycin (mean [6SE]
Kg/m
2, +2.3 [0.9], p=0.03) (Figure 1). No significant BMI
increase was observed with amoxicillin+gentamycin or the other
antibiotics.
Seventeen patients had a BMI increase of $10%: 16 (33.3%) in
the Antibiotic group and only one (2.1%) in the control group
(p,0.0001). This major increase of BMI was observed at a rate of
63.4% after treatment with vancomycin+gentamycin, 25% after
treatment with amoxicillin+gentamycin, and 22.2% after treat-
ment with other antibiotics (p,0.0001). The rate of BMI increase
$10% was significantly higher after vancomycin+gentamycin
treatment than in controls (p,0.0001) or after a treatment by
amoxicillin+gentamycin (p=0.02) or other antibiotics (p=0.06)
(Figure 2). Among all 96 patients assessed, five developed obesity,
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2 after an increase of their BMI
$10%. Three of those had been treated with vancomycin+gen-
tamycin and two with amoxicillin+gentamycin.
After multivariable analysis, treatment with vancomycin+gen-
tamycin remained the only predictor of a major increase of BMI
(adjusted OR, 6.7; 95% CI, 1.37–33.0; p=0.02) (Table 3).
By stratified analysis, the impact of vancomycin on the risk of
increased BMI $10% was particularly high in males (p=0.06), in
patients older than 65 (p=0.01), and in the absence of cardiac
surgery (p=0.03) (Figure 3). Three patients in the study were
males, older than 65, and underwent vancomycin treatment
without surgery. All of them became obese after a BMI increase
$10%, with a weight increase of 20 Kg, 17 Kg, and 10 Kg,
respectively.
No significant difference in lifestyle was noticed according the
different groups.
Discussion
The main result of the present work shows a significant and
persistent weight gain after an episode of IE in patients who had
been treated by vancomycin and gentamycin.
Antibiotics promote weight gain and were among the first
growth promoters used in agriculture. Indeed, avoparcin, a
glycopeptide structurally related to vancomycin, was widely used
in Europe as a growth promoter from the early 1970s until a
recent ban due to the emergence of vancomycin-resistant
enterococci [20]. This antibiotic has been shown to improve feed
efficiency and increases weight gain (WG) in animals [34].
Moreover, previous studies have demonstrated that the use of
antibiotics in humans, especially in infants and children, is also
associated with WG [21]. The mechanism by which antibacterial
agents improve growth performance is not well known, but several
hypotheses have been proposed [16]: (i) nutrients are more
efficiently absorbed because of a thinner small-intestinal epithe-
lium; (ii) nutrients are spared because competing microorganisms
are reduced; (iii) microorganisms responsible for subclinical
infections are reduced or eliminated; (iv) production of growth-
depressing toxins or metabolites by intestinal microflora is
reduced; or (v) modifications of bacterial enzyme activity improve
food efficiency. Thus, there is increasing evidence about the role of
the gut’s microorganisms on the energy conversion of nutriments
[8] and their implications on obesity. This has been supported by
reports involving mouse models with a genetic tendency for obesity
[9,13,15]. A recent 16S rRNA sequencing-based investigation
Table 2. Causes of hospitalization in the 48 controls.
n
Unexplained fever in patients with heart valve disease or PPM or ICD 15
Fever related to an acute degenerative mitral chordae rupture 7
Respiratory tract infection 7
Pericarditis, myocarditis 4
Paraprosthetic leak without IE 5
PPM or ICD local pocket infection 2
Local catheter related infection in patient
with heart valve disease
2
Stroke 1
Chronic lymphoid leukemia 1
Urinary tract infection in patient
with heart valve disease
1
Systemic lupus 1
Fever related to neuroleptic treatment 1
Myxoma 1
PPM=pacemaker; ICD=implantable cardioverter defibrillator.
doi:10.1371/journal.pone.0009074.t002
Table 1. Clinical characteristics of patients in the Antibiotic and control groups.
Antibiotic group Controls p
n=48 n=48 value
Age, mean 6SD, y 59.5614 63.2614 0.20
Male 36 (75) 29 (60.4) 0.13
Baseline* weight, mean 6SD, Kg 75.2617 69.8615 0.10
Baseline* BMI, mean 6SD, Kg/m
2 25.3652 3 . 9 64 0.14
Diabetes 2 (4.2) 1 (2.1) 1.0
Cancer 10 (20.8) 2 (4.2) 0.03
Chronic renal insufficiency 3 (6.3) 1 (2.1) 0.62
Previous heart disease 33 (68.8) 37 (77.1) 0.36
Prosthetic valve 14 (29.2) 18 (37.5) 0.39
Pacemaker, implantable cardioverter defibrillator 11 (22.9) 5 (10.4) 0.10
Stroke 5 (10.4) 0 (0) 0.06
Heart failure 19 (39.6) 19 (39.6) 1.0
Quit smoking
{ 1 (2.5) 1 (2.5) 1.0
Cardiac surgery with the year after admission 35 (72.9) 8 (16.7) ,0.0001
Values are number (%).
BMI=body mass index.
*Baseline is defined as one month before the first symptoms.
{Defined as yes if smokers reported that they had quit smoking since the previous period. Data available in 40 patients.
doi:10.1371/journal.pone.0009074.t001
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lean mammals, mainly due to an increased Firmicutes proportion in
obese mammals [15]. Lactobacillus sp, one of these bacterial
communities with probiotic activity, has an impact on food
conversion and a potential effect on WG, as demonstrated in farm
animals [26,27,28]. Lactobacillus sp treatment results in higher
metabolic activity, lower levels of non-esterified fatty acids,
triglycerides, urea, and an increase in the levels of alkaline
phosphatase and creatine kinase [35]. Vendt et al. treated 120
healthy infants (up to two months), with either regular formula, or
formula supplemented with 10
7 CFU/g L. rhamnosus strain GG.
After six months, the 51 children that received the Lactobacillus-
supplemented formula gained weight more rapidly and displayed
significantly greater body length and weight than those receiving
the regular formula [29].
These well known data concerning the impact of avoparcin and
Lactobacillus sp on WG in animals and humans may explain the
results found with vancomycin in the present study. Indeed,
vancomycin is an analogue of avoparcin, and Lactobacillus sp are
Figure 1. Body mass index (BMI) changes in controls and in patients according to their antibiotic treatment.
doi:10.1371/journal.pone.0009074.g001
Figure 2. Percentage of patients with a major increase ($10%)
of body mass index (BMI), defined as an increase.
doi:10.1371/journal.pone.0009074.g002
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speculate that the weight gain was induced by the growth
promoter effect of Lactobacillus sp in patients who had been treated
by vancomycin. Moreover, a previous study in rats demonstrated
that amoxicillin induced alterations in microbial populations that
included depletion of the Lactobacillus sp [36]. These results are in
accordance with the absence of significant weight gain observed in
our patients treated with amoxicillin.
The empirical data from agriculture and experimental data in
laboratory animals show that manipulating gut microbiota by
antibiotic administration or by colonization with selected bacteria
results in significant WG. We speculate that some antibiotics and
probiotics may have the same effect in humans. A recent study
shows that one cause of an abrupt shift in intestinal microbiota in
babies is antibiotic treatment [10]. Thus, a possible link between
increased antibiotic use and obesity has been recently proposed
[22,37], and our preliminary results add credence to this hypothesis.
Moreover, our stratified analysis showed the impact of three
factors that could influence weight changes during antibiotic
treatment: cardiac surgery, age, and gender. First, cardiac surgery
could have limited the WG in some patients because of a longer
hospitalization, especially in intensive care units where the calorific
intake is not optimal. Second, the fact that older patients had a
greater WG may be explained by a higher proportion of treatment
without surgery in this subgroup. Finally, the trend towards a
greater WG in males could be either related to the fact that
females pay more attention to their weight changes than males in
our country [38] or to the relatively small sample size of females in
the present work.
It should be noted that the present study has several limitations,
including the small sample size and the absence of a systematic,
prospectively collected questionnaire of lifestyle. However, with
our eligibility criteria, the profile of patients in the two groups was
similar because it represents the relatively homogenous sample of
those in whom IE was suspected. Moreover, the history of cancer
that was more frequently noticed in the Antibiotic group
emphasizes the results on weight gain observed in that group.
Finally, our hypothesis about the colonization of the gut by
Lactobacillus sp in patients treated with vancomycin is at this time
only speculative and needs to be confirmed. We are currently
testing this hypothesis.
Table 3. Predictors of an increase of BMI $10%.
Univariate analysis Multivariable analysis
OR 95% CI p Adjusted OR 95% CI p
Age 1.0 0.96–1.04 0.88
Male sex 3.2 0.61–16.7 0.17
Cancer 0.8 0.18–3.73 0.80
Chronic renal insufficiency 1.0 0.08–11.9 1.0
Comorbidity index $2 1.3 0.38–4.65 0.67
Stroke 0.6 0.06–5.58 0.62
Heart failure 0.2 0.23–0.06 0.05 0.2 0.04–1.0 0.05
Cardiac surgery 0.7 0.20–2.76 0.65
Vancomycin+gentamycin 5.4 1.29–23.0 0.02 6.7 1.37–33.0 0.02
Other antibiotics 2.1 0.27–16.8 0.47
Amoxicillin+gentamycin 0.4 0.12–1.39 0.15
doi:10.1371/journal.pone.0009074.t003
Figure 3. Impact of vancomycin treatment on the risk of major
increase of body mass index (BMI $10%) in patients treated for in-
fective endocarditis according to age, gender,andcardiacsurgery.
doi:10.1371/journal.pone.0009074.g003
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Significant and persistent WG can occur after treatment with
high doses of vancomycin in patients with IE. The risk of obesity is
particularly high in vancomycin-treated male patients older than
65 who did not undergo cardiac surgery. If these results are
confirmed by other studies, it will be important to prevent major
WG, possible obesity, and all of their associated consequences after
a long treatment with antibiotics. Hence, we suggest nutritional
programs and weight follow-up in patients undergoing such
treatment, especially those with a history of heart disease. Finally,
we hypothesize that the growth promoter effect of vancomycin
might be explained by the selection of Lactobacillus sp in the gut
microbial flora.
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